Annual report pursuant to Section 13 and 15(d)

Significant Accounting Policies (Narrative) (Details)

v3.24.0.1
Significant Accounting Policies (Narrative) (Details)
12 Months Ended
Jan. 01, 2024
shares
Jan. 01, 2023
shares
Jul. 22, 2016
shares
Dec. 31, 2023
USD ($)
segment
item
Dec. 31, 2022
USD ($)
Significant Accounting Policies          
Number of subsidiaries | item       0  
Number of operating segments | segment       1  
Number of reportable segments | segment       1  
Restricted cash       $ 750,000 $ 1,000,000
Estimated useful life       5 years  
Property, plant and equipment, gross       $ 7,694,000 16,841,000
Research and development       40,513,000 62,475,000
Accumulated other comprehensive loss       0  
Construction in Process [Member]          
Significant Accounting Policies          
Property, plant and equipment, gross       $ 29,000 $ 1,000,000.0
Fortress Biotech, Inc [Member]          
Significant Accounting Policies          
Common stock dividend issued (in shares) | shares 353,086 187,134      
Percentage of fully diluted equity 2.50% 2.50%   2.50% 2.50%
Fortress Biotech, Inc [Member] | License Agreements [Member]          
Significant Accounting Policies          
Research and development       $ 500,000 $ 1,100,000
Fortress Biotech, Inc [Member] | Preferred Class A [Member]          
Significant Accounting Policies          
Preferred stock dividends issued (in shares) | shares     250,000    
Percentage of fully diluted equity     2.50%